Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 5, 1998, Pages 419-424

  D'Haens, G ^a   Verstraete, A ^a   Cheyns, K ^a   Aerden, I ^a   Bouillon, R ^a   Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BUDESONIDE; C REACTIVE PROTEIN; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; MESALAZINE; METHYLPREDNISOLONE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DEFECT; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROHN DISEASE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; BONE AND BONES; BUDESONIDE; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; OSTEOCALCIN;

EID: 0031861430     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00321.x     Document Type: Article

References (18)

1. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-15.
2. Driscoll RH, Meredith SC Jr, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83: 1252-8.
3. Vogelsang H, Ferenci P, Woloszczuk W, et al. Bone disease in vitamin D-defident patients with Crohn's disease. Dig Dis Sci 1989; 34: 1094-9.
4. Baylink DJ. Glucocorticosteroid-induced osteoporosis. N Engl J Med 1983; 300: 306-8.
5. Peck W, Gennari C, Raisz L, et al. Corticosteroids and bone. Calcif Tissue Int 1984; 36: 4-7.
6. Brattsand R, Thale'n A, Roempke K, Kallström L, Gruvstad E. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nuclear fluorination on the topical to systemic activity ratio of glucocorticosteroids. J Steroid Biochem 1982; 16: 779-86.
7. Brattsand RL. Steroid development: a case of enhanced selectivity for the bowel wall. In: Jewell DP, Rutgeerts P, eds. Reviewing Steroids in the Treament of IBD. Res Clin Forum 1993; 15(5): 17-33.
8. Edsbäcker S, Wollmer P, Nilsson A, Nilsson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled-ileal-release (CIR) capsules. Gastroenterology 1993; 104: A695.
9. Löfberg R, Danielsson A, Salde L. Oral budesonide in active ileal Crohn's disease - a pilot trial with a topically acting steroid. Aliment Pharmacol Ther 1993; 7: 611-16.
10. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N. Engl J Med 1994; 331: 836-41.
11. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
12. Campieri C, Ferguson A, Doe W & the International Budesonide Study Group. Oral budesonide compares favorably with prednisolone in active Crohn's disease. Gastroenterology 1995; 108: A790.
13. Bouillon R, Vanderschueren D, Van Herck E, et al. Homologous radioimmunoassay of human osteocalcin. Clin Chem 1992; 38: 2055-60.
14. Yoshioka T, Sato B, Matsumoto K, Ono K. Steroid receptors in osteoblasts. Clin Orthop 1980; 148: 297-303.
15. Peck WA. The effects of glucocorticosteroids on bone cell metabolism and function. In: Avioli LV, Gennari C, Imbimbo BP, eds. Glucocorticoid Effects and Their Biological Consequences, Volume 171. New York: Plenum Press, 1984; 111-19.
16. Brissot C, Meunier PJ, Chapuy MC. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis 1979; 1: 303-11.
17. Silvennoinen JA, Kartunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
18. Price PA, Parthemore JC, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: 878-83.